DeLong Mark Jeffrey 4

What Happened
Mark DeLong, Chief Business & Strategy Officer at Apellis Pharmaceuticals (APLS), was granted 36,606 restricted stock units (RSUs) on January 28, 2026. The reported acquisition price is $0.00 (an award rather than a purchase), so there was no immediate cash outlay or sale; total reported value at grant = $0.

Key Details

• Transaction date: January 28, 2026 (reported on Form 4 filed Jan 30, 2026) — filing appears timely.
• Transaction type/code: A — award/grant (Restricted Stock Units).
• Shares/units granted: 36,606 RSUs; reported acquisition price $0.00; reported total value $0.
• Vesting/footnote: These RSUs vest 25% annually over four years from the grant date, subject to continued service.
• Shares owned after transaction: Not specified in the provided filing.
• No indication of immediate sale, exercise, or tax-withholding in the filing.

Context
RSU grants are a common form of executive compensation and represent a promise of future shares that vest over time; they are not the same as an open-market purchase (which some investors view as a stronger bullish signal). This award increases DeLong’s potential future equity stake as it vests, but does not reflect an immediate cash investment or sale.